"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A study looking at HSV1716 to treat mesothelioma
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study is looking at HSV1716 to treat people with mesothelioma of the chest.
More about this trial
Doctors treat mesothelioma with surgery, radiotherapy or chemotherapy. Unfortunately these don’t always work and so they are looking for new ways to treat mesothelioma.
HSV1716 is a type of virus that infects cancer cells and kills them. We know from
The aim of this study is to find out how safe HSV1716 is to treat people with mesothelioma of the chest.
Who can enter
You may be able to enter this study if you
- Have mesothelioma of the chest (pleural mesothelioma) and can’t have surgery to remove it
- Have a collection of fluid between the sheets of skin which cover the lungs (pleural effusion) and have a tube in place to drain the fluid or need to have a tube put in
- Have satisfactory blood test results
- Are well enough to be up and about for at least half the day (performance status 0, 1, or 2)
- Are willing to take reliable contraception if you or your partner could become pregnant
- Are at least 18 years old
You cannot enter this study if
- You may need to have radiotherapy or chemotherapy to relieve symptoms (
palliative treatment) in the next month
- You have had a treatment similar to HSV1716 before – your doctor can advise
- You have had an experimental drug as part of a clinical trial in the last 2 months
- You are taking more than 5mg of prednisolone a day
- You have had another cancer in the last 5 years apart from basal cell skin cancer or in situ carcinoma of the cervix
- You have a medical condition that is a cause for concern or could affect you taking part in this trial
- The tube you have in place to drain the fluid between the sheets of skin covering your lungs isn’t a type suitable for use in this trial – your doctor can advise about this
- You are pregnant or breastfeeding
This is a phase 1/2 study. It is in 2 parts. Part A will recruit 3 people. Part B will recruit up to 9 people. Everyone will have HSV1716.
People in part 1 have 1 dose of HSV1716. If they don’t have serious side effects then the study will go on to part B.
The first 3 people in part B will have 2 doses of HSV1716. If they don’t have serious side effects the next 6 will have 4 doses. You have 1 dose a week.
HSV1716 is in liquid form and will be pushed into the space around your lungs by putting it into the tube that is used to drain away excess fluid.
You see the doctor to have some tests before taking part in this study. These tests include
- A physical examination
- Blood tests
- Urine test
- Taking a sample of fluid from the tube in your chest
- Mouth swab
- Heart trace (
- Chest X-ray
- CT scan
During treatment you see the doctor regularly to have the same tests apart from the heart trace, chest X-ray and CT scan.
You have a CT scan a month and 2 months after starting treatment.
After treatment you see the doctor every month until HSV1716 can’t be found in the sample of fluid taken from the tube in your chest.
This is the first time HSV1716 has been used to treat mesothelioma. So there may be side effects we don’t know about. Side effects may include
- Flu like symptoms
Inflammationof the lining of the lung
- Lung infection
- Infection where the tube enters your chest
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Penella Woll
Experimental Cancer Medicine Centre (ECMC)
Sheffield Teaching Hospitals NHS Foundation Trust